CONCORD BIOTECH Financial Statement Analysis
|
||
|
The Revenues of CONCORD BIOTECH have increased by 19.20% YoY .
The Earnings Per Share (EPS) of CONCORD BIOTECH has increased by 28.32 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
CONCORD BIOTECH Last 5 Annual Financial Results
[BOM: 543960|NSE : CONCORDBIO]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹1,017 Cr | ₹853 Cr | ₹713 Cr | ₹617 Cr | ₹512 Cr |
| Expenses | ₹585 Cr | ₹505 Cr | ₹439 Cr | ₹289 Cr | ₹308 Cr |
| Operating Profit (Excl OI) | ₹432 Cr | ₹349 Cr | ₹274 Cr | ₹328 Cr | ₹205 Cr |
| Other Income | ₹34 Cr | ₹35 Cr | ₹23 Cr | ₹14 Cr | ₹31 Cr |
| Interest | ₹3.18 Cr | ₹9.80 Cr | ₹6.14 Cr | ₹1.05 Cr | ₹1.17 Cr |
| Depreciation | ₹54 Cr | ₹54 Cr | ₹50 Cr | ₹28 Cr | ₹21 Cr |
| Profit Before Tax | ₹413 Cr | ₹322 Cr | ₹238 Cr | ₹313 Cr | ₹213 Cr |
| Profit After Tax | ₹308 Cr | ₹240 Cr | ₹175 Cr | ₹235 Cr | ₹169 Cr |
| Consolidated Net Profit | ₹308 Cr | ₹240 Cr | ₹175 Cr | ₹235 Cr | ₹169 Cr |
| Earnings Per Share (Rs) | ₹29.45 | ₹22.95 | ₹183.92 | ₹246.92 | ₹177.66 |
| PAT Margin (%) | 30.30 | 28.14 | 24.10 | 37.35 | 32.33 |
| ROE(%) | 21.88 | 20.06 | 16.64 | 26.55 | 21.94 |
| ROCE(%) | 29.13 | 26.70 | 21.66 | 32.96 | 26.23 |
| Total Debt/Equity(x) | 0.00 | 0.02 | 0.05 | 0.09 | 0.06 |
Key Financials |
||
| Market Cap | : | ₹ 17,534.6 Cr |
| Revenue (TTM) | : | ₹ 1,089.2 Cr |
| Net Profit(TTM) | : | ₹ 328.2 Cr |
| EPS (TTM) | : | ₹ 31.4 |
| P/E (TTM) | : | 53.4 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| CONCORD BIOTECH | 1.1% | 3% | 15% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.8% | 7.6% | 8.4% |
| DIVIS LABORATORIES | -2.3% | 0.8% | 72.7% |
| CIPLA | -5.4% | -1.5% | 0.8% |
| TORRENT PHARMACEUTICALS | -0.8% | 6.8% | 25.6% |
| DR REDDYS LABORATORIES | -5.5% | 1.6% | -5.1% |
| MANKIND PHARMA | 2.1% | 3.7% | 9.5% |
| ZYDUS LIFESCIENCES | -4.4% | 0.4% | -12.5% |
| LUPIN | -4.5% | 6.9% | 25.2% |
CONCORD BIOTECH Revenues
[BOM: 543960|NSE : CONCORDBIO]
| Y-o-Y | 19.20 % |
| 5 Yr CAGR | 18.70 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,017 Cr | 19.20 | |
| Mar2023 | ₹853 Cr | 19.67 | |
| Mar2022 | ₹713 Cr | 15.56 | |
| Mar2021 | ₹617 Cr | 20.42 | |
| Mar2020 | ₹512 Cr | - | |
CONCORD BIOTECH Operating Profit
[BOM: 543960|NSE : CONCORDBIO]
| Y-o-Y | 23.99 % |
| 5 Yr CAGR | 20.57 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹432 Cr | 23.99 | |
| Mar2023 | ₹349 Cr | 27.25 | |
| Mar2022 | ₹274 Cr | -16.47 | |
| Mar2021 | ₹328 Cr | 60.33 | |
| Mar2020 | ₹205 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 4.01 % |
| 5 Yr CAGR | 1.58 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 42.5% | 4.01 | |
| Mar2023 | 40.86% | 6.35 | |
| Mar2022 | 38.42% | -27.71 | |
| Mar2021 | 53.15% | 33.14 | |
| Mar2020 | 39.92% | - | |
CONCORD BIOTECH Profit After Tax
[BOM: 543960|NSE : CONCORDBIO]
| Y-o-Y | 28.33 % |
| 5 Yr CAGR | 16.21 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹308 Cr | 28.33 | |
| Mar2023 | ₹240 Cr | 37.25 | |
| Mar2022 | ₹175 Cr | -25.51 | |
| Mar2021 | ₹235 Cr | 38.99 | |
| Mar2020 | ₹169 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 7.68 % |
| 5 Yr CAGR | -1.61 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 30.3 % | 7.68 | |
| Mar2023 | 28.14 % | 16.76 | |
| Mar2022 | 24.1 % | -35.48 | |
| Mar2021 | 37.35 % | 15.53 | |
| Mar2020 | 32.33 % | - | |
CONCORD BIOTECH Earnings Per Share (EPS)
[BOM: 543960|NSE : CONCORDBIO]
| Y-o-Y | 28.32 % |
| 5 Yr CAGR | -36.19 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹29 | 28.32 | |
| Mar2023 | ₹23 | -87.52 | |
| Mar2022 | ₹184 | -25.51 | |
| Mar2021 | ₹247 | 38.98 | |
| Mar2020 | ₹178 | - | |
CONCORD BIOTECH Return on Capital Employed (ROCE)
[BOM: 543960|NSE : CONCORDBIO]
| Y-o-Y | 9.10 % |
| 5 Yr CAGR | 2.66 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 29.13% | 9.10 | |
| Mar2023 | 26.7% | 23.27 | |
| Mar2022 | 21.66% | -34.28 | |
| Mar2021 | 32.96% | 25.66 | |
| Mar2020 | 26.23% | - | |
CONCORD BIOTECH Share Price vs Sensex
| Current Share Price | : | ₹1,676.4 |
| Current MarketCap | : | ₹ 17,534.6 Cr |
| Updated EOD on | : | Mar 28,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CONCORD BIOTECH | 1.1% |
3% |
15% |
| SENSEX | 0.7% |
4% |
6.3% |
CONCORD BIOTECH related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 1.5% | 3.4% | 7.5% |
| BSE 500 | 0.3% | 4.3% | 6.2% |
| BSE 500 SHARIAH | -0.2% | 1.8% | 0.3% |
| BSE 400 MIDSMALLCAP INDEX | -0.7% | 3.8% | 8.1% |
| BSE MIDSMALLCAP | -1.1% | 3.4% | 8.1% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 500 | 0.3% | 4.3% | 6.7% |
| NIFTY TOTAL MARKET | 0.2% | 4.1% | 6.8% |
| NIFTY500 MULTICAP 50:25:25 | -0% | 4.1% | 7.4% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | -0.2% | 4% | NA |
| NIFTY MIDSMALLCAP 400 | -0.6% | 3.6% | 8.3% |
You may also like the below Video Courses
FAQ about CONCORD BIOTECH Financials
How the annual revenues of CONCORD BIOTECH have changed ?
The Revenues of CONCORD BIOTECH have increased by 19.20% YoY .
How the Earnings per Share (EPS) of CONCORD BIOTECH have changed?
The Earnings Per Share (EPS) of CONCORD BIOTECH has increased by 28.32 % YoY .
Check out Intrinsic Value of Peers of CONCORD BIOTECH
Compare Stock Analytics of Peers of CONCORD BIOTECH
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
